Analyst Ratings For Aimmune Therapeutics (NASDAQ:AIMT)
Today, Roth Capital raised its price target on Aimmune Therapeutics (NASDAQ:AIMT) to $80.00 per share.
Some recent analyst ratings include
- 3/5/2018-Cantor Fitzgerald Reiterated Rating of Overweight.
- 2/23/2018-Wedbush Reiterated Rating of Buy.
Recent Insider Trading Activity For Aimmune Therapeutics (NASDAQ:AIMT)
Aimmune Therapeutics (NASDAQ:AIMT) has insider ownership of 17.59% and institutional ownership of 62.04%.
- On 2/26/2018 Eric Bjerkholt, CFO, bought 3,125 with an average share price of $32.00 per share and the total transaction amounting to $100,000.00.
- On 2/26/2018 Kathryn E Falberg, Director, bought 30,000 with an average share price of $32.00 per share and the total transaction amounting to $960,000.00.
- On 2/22/2018 Bakker Juliet Tammenoms, Major Shareholder, bought 9,375 with an average share price of $32.00 per share and the total transaction amounting to $300,000.00.
- On 2/22/2018 Patrick G Enright, Director, bought 15,593 with an average share price of $32.00 per share and the total transaction amounting to $498,976.00.
- On 2/5/2018 Douglas T Sheehy, Insider, sold 1,648 with an average share price of $35.87 per share and the total transaction amounting to $59,113.76.
- On 2/1/2018 Mary M Rozenman, Insider, sold 6,592 with an average share price of $35.36 per share and the total transaction amounting to $233,093.12.
- On 1/24/2018 Douglas T Sheehy, Insider, sold 1,875 with an average share price of $38.15 per share and the total transaction amounting to $71,531.25.
Recent Trading Activity for Aimmune Therapeutics (NASDAQ:AIMT)
Shares of Aimmune Therapeutics closed the previous trading session at with 35.25 shares trading hands.
